Casale, Thomas B.
Gimenez-Arnau, Ana Maria
Bernstein, Jonathan A.
Holden, Michael
Zuberbier, Torsten
Maurer, Marcus
Article History
Received: 26 July 2023
Accepted: 13 September 2023
First Online: 30 September 2023
Declarations
:
: Jonathan A. Bernstein has served as a consultant and speaker bureau member for Genentech, Inc. Thomas B. Casale has served as a consultant and speaker bureau member for Genentech, Inc., and a consultant for Novartis Pharmaceuticals Corporation. Ana Maria Giménez-Arnau is or recently was a speaker and/or advisor for and/or has received research funding from Almirall, Amgen, AstraZeneca, Avene, Celldex, Escient Pharmaceuticals, Genentech, GSK, Instituto Carlos III- FEDER, Leo Pharma, Menarini, Novartis, Sanofi–Regeneron, Servier, Thermo Fisher Scientific, Uriach Pharma/Neucor. Michael Holden is an employee of Genentech, Inc., and a stockholder in Roche. Marcus Maurer has been a speaker and/or advisor for and/or has received research funding from Allakos, Amgen, Aralez, ArgenX, AstraZeneca, Celldex, Centogene, CSL Behring, Eli Lilly, FAES, Genentech, GI Innovation, GSK, Innate Pharma, Kyowa Kirin, Leo Pharma, Menarini, Moxie, Novartis, Pfizer, Roche, Sanofi/Regeneron, Third Harmonic Bio, UCB Pharma, and Uriach. Torsten Zuberbier has received institutional funding for research and/or honoraria for lectures and/or consulting from AbbVie, ALK, Almirall, Amgen, Astellas, AstraZeneca, Bayer Health Care, Bencard, Berlin Chemie, FAES, HAL, Henkel, Kryolan, Leti, L’Oreal, Meda, Menarini, Merck, MSD, Novartis, Pfizer, Sanofi, Stallergenes Greer, Takeda, Teva, UCB Pharma, and Uriach, and is a member of ARIA/WHO, DGAKI, ECARF, GA<sup>2</sup>LEN, and WAO.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.